Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for a severe type of asthma, pulmonary arterial hypertension and inflammatory bowel disease, this IPO could be particularly appealing to investors. However, despite the promise associated with this biotech, there are also a number of potential problems that prospective investors should be aware of. For more, CLICK HERE.
Low-priced stocks offer investors – especially more aggressive traders – the opportunity to not only make a decent profit in the event of even relatively small price moves, but also to buy more shares than they would be able to of large-cap stocks. Today’s article highlights five stocks trading under $10 that the authors believe “While more suited for aggressive accounts… could prove exciting additions to portfolios looking for solid alpha potential.” For these five stocks, CLICK HERE.
“You don’t usually get the chance to pick up the entire research-and-development arm of a major company for free,” acknowledges the author of today’s article – but he proceeds to highlight how, in the aftermath of the stock market rout, shares of some biotech companies have been pushed down to the point where investors get those companies’ pipelines “just about for free.” For two such biotechs – as well as a third which may still be a good deal despite having rebounded – CLICK HERE.
The biotech sector outperformed the S&P 500 last year – and further strong performance could lie ahead thanks in part to the tax break for companies that repatriate funds from overseas, which could stimulate mergers and acquisitions. As the author of today’s article acknowledges, “That could be big news for some of the smaller players that have promising drugs in the pipeline.” He proceeds to highlight three biotech stocks with catalysts that give them massive upside potential – including a potential acquisition target. For more, CLICK HERE.
While the key to successful investing – regardless of what you are investing in – is minimizing risk while maximizing potential reward, how you go about accomplishing this can depend on what you are investing in. In particular, when it comes to investing in biotech stocks, the author of today’s article notes that they have their “own unique requirements” in this regard – and he proceeds to outline “seven essential rules” for biotech investing that can help increase one’s odds of success. CLICK HERE.
Biotech stocks are hot right now – and history suggests that things will only get hotter for certain biotech exchange-traded funds and stocks in July and beyond. Today’s article notes that July has been the best month of the year for the SPDR S&P Biotech ETF historically, and highlights three biotech stocks that have historically been among the best stocks to own in July specifically, as well as the third quarter and second half of the year. To find out what these three biotechs are – and for the best performing ETFs and stocks from all sectors in July, the third quarter and the second half of the year historically, CLICK HERE.
A number of conferences have recently taken place where cancer researchers have revealed the latest and most promising developments in the fight against this disease. Today’s article highlights critical advances in two existing cancer therapies – one which allows the immune system to find otherwise invisible tumors and another in which the white blood cells of blood cancer patients are genetically altered so they can better fight the disease – as well as three biotech companies that the author sees as the best pure plays on these advances for investors. To read more, CLICK HERE.
The author of today’s article notes that, over the past year, biotech stocks have underperformed the market, “a surprising turnaround based on their usual tendency to lead the market.” However, the author further acknowledges that the sector’s underperformance is most likely the result of politics (namely rhetoric surrounding high drug prices) rather than some fundamental change, and that the sector will have both winners and losers. In an attempt to identify potential winners, five biotech stocks are highlighted which are trading at low prices (under $5) and growing earnings. To read about these five stocks, CLICK HERE.
After being weighted down this year by the prospect of a Hillary Clinton administration focused on curbing drug prices, biotechs have seen a recovery since the unexpected victory of Donald Trump, whose campaign rhetoric suggests that he will be friendlier towards the industry. With this reversal of fortunes for the biotech sector, it may be worth considering the four biotech stocks recommended in today’s article, which was written before Trump even pulled off his surprise upset over Clinton. To read about these four biotechs that the author believes have the potential for market-beating gains – including the developer of the first noninvasive test for colorectal cancer – CLICK HERE.
With biotech and pharmaceutical stocks struggling of late, where are money managers who still want to have some health care sector exposure putting their money? Today’s article highlights one part of the health care sector that “Mad Money” host Jim Cramer states is “on fire”: the medical device segment. What factors are leading money managers to buy medical device stocks “hand over fist”, and why is Cramer confidently declaring “So, when it comes to the medical device space, I say take your pick”? CLICK HERE to find out.